START-up firm AilseVax, which is developing the next generation of cancer vaccines, has become the 100th company to spin out of the laboratories at Belfast's Queen’s University.
Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (Queen’s). Aviceda’s HALOS™ (High-Affinity .
Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen's.
INNOVATIVE ACCESS DEAL SECURED IN THE UK FOR LYNPARZA (OLAPARIB) TO TREAT BRCA-MUTATED CANCERS Olaparib is the first and only treatment available within NHS England for patients with germline BRCA mutations in early breast cancer (stage I-IIIA) and patients with metastatic castration-resistant prostate cancer (.